



Published in final edited form as:

Neuroscience. 2007 April 25; 146(1): 415–426.

Reduced Basal and LPS-Stimulated A₁AR Expression in the Brain of NF-κB p50^{-/-} Mice

Krishna A. Jhaveri¹, Joel Reichensperger¹, Linda A. Toth¹, Yuko Sekino², and Vickram Ramkumar¹

¹ Department of Pharmacology Southern Illinois University School of Medicine PO Box 19629 Springfield, Illinois 62794–9629

² Division of Neuronal Network Department of Basic Medical Sciences Institute of Medical Science University of Tokyo, Tokyo, Japan

Abstract

Adenosine promotes cytoprotection under condition of infection, ischemic preconditioning and oxidative stress. Previous studies from our laboratory indicate that the expression of the adenosine A₁ receptor (A₁AR) is induced by oxidative stress via activation of nuclear factor (NF)-κB. The prototypic transcription factor is comprised of homo- or heterodimers of p50 and p65 subunits. To determine the role of NF-κB in the regulation of the A₁AR *in vivo*, we compared the A₁AR RNA and protein levels in the brains of mice lacking the p50 subunit of NF-κB (p50^{-/-} mice) and age-matched B6129PF2/J (F2) controls. Radioligand binding assays in the cortex revealed a significantly lower number of A₁AR (B_{max}) in the cortex of p50^{-/-} mice (151 ± 62 fmol/mg protein) versus 479 ± 181 fmol/mg protein in the F2 (N=5 per strain, p < 0.05), but no change in K_d. Similar reductions in A₁AR were measured in the hippocampus, brain stem and hypothalamus and in peripheral tissues, such as the adrenal gland, kidney and spleen. Estimation of the A₁AR following purification by antibody affinity columns also indicated reduced A₁AR in the p50^{-/-} mice cortex, as compared to the F2 mice. A₁AR immunocytochemistry indicates distinct neuronal labeling in the F2 cortex, which was substantially reduced in similar sections obtained from p50^{-/-} mice. p50^{-/-} mice expressed lower levels of A₁AR mRNA than F2 mice, as determined by real time PCR. Quantitation of the A₁AR transducing G proteins by Western blotting show significantly less G_{αi3}, no change in G_{αi1}, but higher levels of G_{αo} and G_β in the cortices of p50^{-/-}, as compared to F2 mice. Administration of bacterial lipopolysaccharide (LPS), an activator of NF-κB, increased A₁AR expression in the cortices of F2 mice but not p50^{-/-} mice. Cortical neurons cultures prepared from p50^{-/-} mice showed a greater degree of apoptosis, compared to neurons from F2 mice. Activation of the A₁AR reduced apoptosis with greater efficacy in cultures from F2 than p50^{-/-} mice. Taken together, these data support a role for NF-κB in determining both the basal and LPS-stimulated A₁AR expression *in vivo* which could contribute to neuronal survival.

Keywords

NF-κB; A₁ adenosine receptor; lipopolysaccharide; central nervous system

Send correspondence and reprint requests to: Vickram Ramkumar, Ph.D. Department of Pharmacology SIU School of Medicine PO Box 19629 Springfield, IL 62794–9629 Phone: 217–545–2171 Fax: 217–545–0145 Email: vramkumar@siumed.edu

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

Extracellular purines (adenosine, ADP and ATP) are important signaling molecules that regulate various biological processes, including neurotransmission in peripheral and central nervous systems, sleep homeostasis, and the immune response (Ralevic and Burnstock, 1998). Adenosine exerts its physiologic roles by interacting with seven distinct transmembrane adenosine receptors (ARs), whose actions are in turn mediated by different heterotrimeric G proteins and effector systems (Fredholm et al., 2001). Four subtypes of adenosine receptors, A₁, A_{2a}, A_{2b}, and A₃, have been identified based on molecular cloning studies, tissue distribution, and pharmacologic profiles (Olah and Stiles, 1992; Tucker and Linden, 1993). The A₁AR is the principal AR subtype in the central nervous system, with wide distribution in the cortex, cerebellum, thalamus and hippocampus (Olah and Stiles, 1992; Rivkees et al., 1995). Stimulation of A₁AR suppresses the presynaptic release of excitatory amino acids, such as glutamate (Dolphin and Archer 1983). In addition, activation of pre-synaptic A₁AR in turn activates K⁺ conductance (Fredholm and Dunwiddie, 1988) and inhibits Ca²⁺ influx into the nerve terminals (Rudolphi et al., 1992), thereby leading to neuronal hyperpolarization and reduced neuronal firing rate (Kostopoulos and Phillis, 1977). Activation of the A₁AR also inhibits adenylyl cyclase activity and voltage-dependent Ca²⁺ channels (Olah and Stiles, 1992).

A neuroprotective role of A₁AR can be demonstrated during conditions of ischemia, hypoxia, and hypercapnea (Rubio et al., 1975; Van Wylen et al., 1986). Adenosine analogues protect against cerebral ischemia in rats (Evans et al., 1987), whereas the AR antagonist, caffeine, exacerbates ischemic damage. Furthermore, studies from our laboratory indicate that during oxidative stress, the A₁AR is induced through activation of NF-κB both *in vitro* (Nie et al., 1998; Pingle et al., 2004) and *in vivo* (Ford et al., 1997; Ramkumar et al., 2004) and is protective under these circumstances.

However, the impact of NF-κB on regulation of basal expression of the A₁AR is unknown, although the constitutive expression of this receptor has been linked to the activator protein (AP)-1 transcription factor (Ren and Stiles, 1995). In this study, we address this question by studying mice that genetically lack the p50 subunit of NF-κB. The p50 and p65 proteins are the prototypic subunits of NF-κB, which exists as homo- or heterodimers in the central nervous system (Kaltschmidt et al., 1994). Mice that lack the p65 subunit of NF-κB die on day 16 (Beg et al., 1995). In contrast, p50 knockout mice survive to adulthood and have a relatively normal phenotype, albeit with some immune system deficits (Sha et al., 1996).

Our data support a role of NF-κB in determining both the basal and stimulated expression of the A₁AR and some of its coupling G protein subunits. Regulating the expression of neuronal A₁AR could contribute to the cytoprotective role of NF-κB *in vivo*.

Materials and Methods

Animal care

Adult male B6129PF2/J (F2) and B6;129P2-Nfkb 1<tm 1 Bal> (p50^{-/-}) mice, were purchased from the Jackson Laboratory (Bar Harbor, ME). The p50^{-/-} mice were homozygous for deletion of the gene for the p50 subunit of NF-κB, and thus are incapable of producing the p50 protein. Since p50^{-/-} mice from the Jackson Laboratory are maintained on a mixed C57BL/6 × 129P3/J, F2 hybrids were used as the control strain, as recommended by the vendor. F2 mice were housed in standard cages and maintained on a 12:12 h light: dark cycle at an ambient temperature of 22 ± 1°C. Rodent laboratory chow (Lab Diet 5001, Nutrition International, Inc., Brentwood, MO) and drinking water were provided ad libitum. Because of subtle immune impairments, p50^{-/-} mice were housed in autoclaved cages, provided with autoclaved food

and water, and maintained in separate chambers to reduce exposure to infection. Mice were at least 8–10 weeks of age (22–28 g) at the time of experimental use. All procedures used in this study were approved the Animal Care and Use Committee at Southern Illinois University, School of Medicine.

Chemicals and drugs

HEPES, Tris HCl, soybean trypsin inhibitor, pepstatin, benzamidine, lipopolysaccharide (LPS) (*E. coli* O111:B4), adenosine deaminase (ADA), polyethyleneimine, 3-[(3-cholamidopropyl) dimethylammonio]-1 propanesulphonate (CHAPS), and 1,3-diisopropyl-8-cyclopentylxanthine (DPCPX) were purchased from Sigma Chemical Company (St. Louis, MO). *R*-phenylisopropyladenosine (*R*-PIA) was purchased from Boehringer-Mannheim Biochemicals (Indianapolis, IN). Rat pheochromocytoma PC12 cells were purchased at passage 2 from the American Type Culture Collection (Manassas, VA). Cell culture supplies were obtained from GIBCO BRL (Grand Island, NY). [³H]-DPCPX (160 Ci/mmol) was purchased from Perkin Elmer (Boston, MA). [¹²⁵I]Na was purchased from Du-Pont New England Nuclear Centre (Boston, MA). Dr. E.M. Schwarz, University of Rochester Medical Center (Rochester, NY), generously provided the adenovirus vector containing the mutant form of IκB-α (mIκB-α).

Sample collection and membrane preparation

For analysis of A₁AR in F2 and p50^{-/-} mice, mice were anesthetized under isoflurane and sacrificed by cervical dislocation. A second set of mice of each strain were treated with LPS (10 μg) and sacrificed 4 hours later for analysis of A₁AR expression. Whole brains were removed and cortex, hippocampus, brain stem, and hypothalamus were dissected under aseptic conditions. In addition, kidneys, spleen, heart and adrenal glands were also dissected from the same animals. The frozen tissues (different brain regions and peripheral tissues) from F2 and p50^{-/-} mice were allowed to thaw on ice and were rinsed with 1 ml of ice cold phosphate-buffered saline (PBS) containing 5 mM EDTA. Tissues were lysed in 1 ml of 10 mM Tris HCl buffer, pH 7.4, containing 5 mM EDTA, 1 mM MgCl₂, 10 μg/ml soybean trypsin inhibitor, 10 μg/ml benzamidine, and 2 μg/ml pepstatin (Buffer A) and homogenized briefly with a Polytron homogenizer (Brinkmann Instruments, Westbury, NY). Membrane fractions were obtained by differential centrifugation. The homogenates were centrifuged at 1,000 g for 10 min at 4°C, followed by centrifugation of the supernatant at 100,000 g for 15 min at 4°C. The final pellet was resuspended in 50 mM Tris -HCl buffer, pH 7.4, 10 mM MgCl₂, and 1 mM EDTA (containing protease inhibitors, as above, buffer A), subjected to brief sonication for 10 sec to give a final membrane protein concentration of ~1 mg/ml. The resuspended fraction containing crude membrane was used for determining receptor densities by radioligand binding after pretreatment with adenosine deaminase (5 units/ml) at 37°C for 10 min to degrade the endogenous adenosine (for radioligand binding studies).

SDS-PAGE analysis and Western blotting

To detect the p50 subunit and G-protein subunits, spleen and cortex from each strain were gently homogenized in Buffer A. The homogenates were centrifuged at 1,000 g for 5 min to remove cellular debris. The supernatant was further centrifuged at 100,000 g for 10 min at 4°C and the pellet obtained, consisting of crude membranes, were used for Western blotting analyses. The membrane fraction (~50 μg protein) was mixed with SDS-PAGE solubilization buffer and resolved on a 12% polyacrylamide gel. Proteins were transferred to nitrocellulose membranes, blocked in Blotto buffer (130 mM NaCl, 2.7 mM KCl, 1.8 mM Na₂HPO₄, 1.5 mM KH₂PO₄, 0.1% NaN₃, 0.1% Triton-X 100, and 5% low-fat skim milk) for 2 h, and then incubated with specific primary antibody for p50 (sc-1190) (Santa Cruz Biotechnology, Santa Cruz, CA) and for G-proteins (kindly provided by Dr. Tom Gettys, Experimental Obesity

Division, Pennington Basic Research Center, Baton Rouge, LA) at 4°C overnight. After five washes in blocking solution, blots were incubated with horseradish peroxidase-labeled secondary antibody (Santa Cruz Biotechnology) for 1 h at room temperature, washed five times with Tris-buffered saline, treated with Enhanced Chemiluminescence Plus reagents (Amersham Pharmacia Biotech, Piscataway, NJ), and then exposed to Kodak XAR film at room temperature. The bands were normalized to an internal control protein (β -actin), and band intensities were determined by densitometry on SynGene Tools software for analysis (Cambridge, England).

Radioligand binding assay

Membrane proteins (~50 μ g) from various regions of F2 and p50^{-/-} mice and 80 μ g of whole cell lysates from PC12 cells (see below) were used to evaluate A₁AR binding. Radioligand binding experiments were performed using the selective A₁AR antagonist [³H]-DPCPX in a concentration of 1 nM for single point binding assays or a range of concentrations (0.25 to 5 nM) for saturation analyses. Radioligand binding assays were performed in a total reaction volume of 250 μ l of buffer A, incubated at 37°C for 1 h, in the absence (total binding) or presence of 1 mM theophylline (to define nonspecific binding, which usually ranged from 10 to 40% of total binding (in different tissues)). Subsequently, samples were filtered through polyethyleneimine-treated (0.05%) Whatman GF/B glass-fiber filters (Brandel, Gaithersburg, MD) using a cell harvester (Brandel, Gaithersburg, MD) and washed with 9 ml (3 washes) ice-cold Tris buffer, pH 8.26 containing 0.01% CHAPS. The filters were allowed to extract overnight in a toluene-based scintillation fluid before measuring the radioactive content of each filter by a liquid scintillation counter (LS5801) (Beckman Instruments, Fullerton, CA). For competition binding assays, increasing concentrations of R-PIA were used to inhibit the binding of 1.0 nM [³H]-DPCPX. Radioligand binding data was plotted and analyzed using GraphPad Prism 4.0 software (GraphPad Software Inc, San Diego, CA).

Immunoprecipitation of A₁AR from pure membrane fraction

Immunoprecipitation was performed according to the protocol contained in the Seize X Mammalian Immunoprecipitation kit (Pierce, Rockford, IL). Briefly, A₁AR antibody affinity columns were prepared with 50 μ g of goat polyclonal A₁AR antibody (Santa Cruz Biotechnology) that was cross-linked to immobilized protein G (50% slurry) in mini columns (one column per sample) and incubated overnight to allow binding of antibodies to protein G. Disuccinimidyl suberate (DSS) was then added to cross-link bound antibody to the support. Membrane fractions were prepared by differential centrifugation as described above from cortex of F2 and p50^{-/-} mice (n = 4 per strain) and solubilized with reagent provided in kit and incubated with the A₁AR affinity column at 4°C overnight for two days to allow ample time for interaction of the A₁AR antibody with the membrane fraction. Columns were washed several times with the binding buffer, and the bound A₁AR was eluted in 200 μ l of elution buffer, pH 2.0. The elute containing purified A₁AR was neutralized in buffer A and used for single point binding with [³H]-DPCPX as described above, or iodinated and used for SDS-PAGE analysis (described below).

Iodination and quantification of purified cortical A₁AR

The purified A₁AR was incubated with 0.1 mCi ¹²⁵I-Na in a total volume of 250 μ l of 50 mM potassium phosphate buffer (pH 7.5), containing 10 μ g chloramine T, for 1 min. The reaction was stopped by adding 100 μ l of sodium metabisulphite (2.4 mg/ml) and the mixture desalted in buffer B (50 mM Tris-HCl buffer, 10mM MgCl₂, and 1mM EDTA, pH 7.4 containing 0.01% CHAPS) on Sephadex G25 columns. The eluates were collected as the iodinated A₁AR. The labeled purified A₁AR was then resolved on a 12% SDS-PAGE gel, loaded with equal amounts of iodinated A₁AR. The gel was dried for 1 h at 60°C using a vacuum operated

gel dryer and, visualized by exposure to Kodak XAR films. Gel sections corresponding to the A₁AR were removed for quantitation of radioactivity in a gamma counter.

Immunohistochemistry

Each mouse was deeply anesthetized with near lethal doses of a mixture of ketamine and xylazine. The chest was opened, a needle was inserted into the left ventricle, and the descending aorta was opened. Perfusion involved sequential injection of 0.9% saline solution (until the blood was washed out), followed by 4% paraformaldehyde for 2 min. The mouse was then decapitated, whole brain was removed, and stored overnight at 4°C in a capped vial containing 4% paraformaldehyde. Sagittal sections were carried out in the midline of the mouse brain and the two hemisections were paraffin-embedded and manually sectioned (10 µm thick) using a Leica RM2125 microtome (Wetzlar, Germany). Sections were placed on Vectabond reagent processed glass slides (Vector Laboratories, Burlingame, CA) and air-dried overnight at room temperature. Sections were de-paraffined in xylene (3 washes), followed by rehydration in decreasing concentrations (100, 95 and 70%) of ethanol.

For immunohistochemistry, sections were rinsed with PBS, blocked for 1 h in 5% normal donkey serum with 0.03% triton X-100 in PBS at room temperature, and then incubated overnight (at 4°C) with a monoclonal A₁AR antibody (Ochiishi et al., 1999). Sections were rinsed with PBS and incubated with TRITC conjugated donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) diluted at 1:50 for 2 h at room temperature. After four rinses in PBS, cover slips were mounted on glass microscope slides using Aquamount, and cells were visualized using an Olympus confocal laser scanning microscope (Melville, NY) with krypton laser at 568 nm using a 20X objective.

Nissl staining with cresyl violet was also performed on adjacent sections from the same brain. After sections were de-paraffinized and rehydrated, they were placed in 2.0 g/L of cresyl violet (Sigma-Aldrich) for 5 min. The sections were then rinsed in water to remove any excess cresyl violet, differentiated in acidified 95% ethanol, rinsed in water to stop the differentiation, and dehydrated with increasing concentrations of alcohol (70, 95, and 100%) and xylene rinses. Sections were then mounted on glass microscope slides using permount, allowed to dry overnight and visualized using Olympus Optical system (Melville, NY).

Real Time PCR

Total RNA extraction was carried out from cortex of F2 and p50^{-/-} mice using the RNeasy Mini Kit (Qiagen Science, Valencia, CA) according to manufacturer's instructions. Samples of total RNA (1 µg each) were reverse transcribed to cDNA using iScript cDNA synthesis kit (BioRad, Hercules, CA). The reaction mix contained 1 µg of total RNA, 4 µl of iScript reaction mix, and 1 µl of iScript reverse transcriptase. Nuclease free water was added to bring the total volume to 20µl. The reaction mix was incubated at 25°C for 5 min, 42°C for 30 min and 85°C for 5 min and 1 µl of this reaction volume was used for real time PCR.

Gene transcripts were quantified using iQTM SYBR Green Supermix kit (BioRad) and the Smart Cycler Real-Time PCR system (Cepheid Inc., Sunnyvale, CA). The final PCR reaction mix (total reaction volume= 25 µl) contained 1 µl of cDNA (diluted 1:5 of the original cDNA extract prepared above), 1.5 µl (~10 pmol) of each primer sequence, 12.5 µl of iQ SYBR Green Supermix reagent (BioRad) and 8.5 µl of sterile nuclease free water. GAPDH expression was used to normalize the amount of cDNA in each sample. Primers were purchased from Integrated DNA Technologies (Coralville, CA) and were as follows: A₁AR primers (Gene Bank accession # NM009629), sense primer: 5'- CATTGGGCCACAGACCTACT-3', antisense primer: 5'- CAAGGGAGAGAATCCA GCAG-3'; GAPDH primers (Gene Bank accession # BC083149), sense primer: 5'- AACGACCCCTTCATTGAC- 3', antisense primer: 5'-

GAAGACACCGTAGACT CCAC – 3'. Negative control experiments were performed without the addition of template cDNA. Cycling conditions were: 95°C for 3 min followed by 45 cycles at 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. On completion of amplification, melting curve analysis was performed by cooling the reaction to 60°C and then heating slowly to 95°C, according to manufacturer's instructions (Cepheid systems). The cycle number at which the sample reaches the threshold fluorescent intensity was termed the cycle threshold (Ct). The relative changes in mRNA levels between basal F2 (1) and p50^{-/-} (2) or between saline- (1) or LPS-treated (2) cortices were measured using the formula: $2^{-(Ct \text{ Target gene1} - Ct \text{ GAPDH1}) - (Ct \text{ Target gene2} - Ct \text{ GAPDH2})}$ (Soong et al., 2001). Relative changes in mRNA levels between samples were expressed as a percentage of the mean of control values. End reaction products were visualized on ethidium bromide stained 1% agarose gels to verify correct product sizes.

Cell culture

Pheochromocytoma (PC12) cells—PC12 cells were cultured in RPMI 1640 media supplemented with 10% equine serum (HS), 5% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 units/ml streptomycin. Culture flasks and plates were coated with 0.1 mg/ml poly-D-lysine prior to plating. All cultures were maintained as a monolayer at 37°C, in 5% CO₂/95% ambient air; with the media replaced every 2–3 days. PC12 cells stably transfected with pCMX-IκB-αM or with an empty vector and were cultured in a similar manner, except that 100 μg/ml G418 sulphate was added to the medium. The mutant form of IκB-α has serine-to-alanine substitutions at positions 32 and 36. The mutant IκB-α (mIκB-α) was generated and characterized previously as a dominant negative inhibitor of NF-κB (Van Antwerp et al., 1996; Schwarz et al., 1998; Nie et al., 1999).

Cortical neuronal culture—In brief, neurons were isolated from the cortex of adult (10–12 week old) B6129PF2/J and p50 KO mice according to established procedures (Brewer et al., 1993; Brewer, 1997). Culture media were obtained from GIBCO Laboratories (Grand Island, NY). Before the addition of test substances, neurons were cultured on cover slips for 10 days in B27/NeurobasalA, containing 5 ng/ml fibroblast growth factor and platelet derived growth factor serum-free media, with 0.5 mM glutamine. The cultures contain a mixture of about 80% neurons, 5% microglia, 10% oligodendroglia, and less than 5% astroglia, based on immunostaining (Brewer, 1997). After a complete change to fresh medium, *R*-PIA (10 μM) and/or DPCPX (1 μM) were added. Cultures were further incubated for 24 h. Another set of neurons were treated similarly in the presence of hydrogen peroxide (10 μM). This procedure does not impose amino acid starvation coincident with the treatment and maintains the neurons in a standard medium that includes vitamin E and three other anti-oxidants. For this reason, toxicity is low as compared to other common protocols (Brewer et al., 1993).

Apoptosis Detection

Apoptosis was detected in cortical neurons using terminal deoxynucleotidyl transferase-mediated digoxigenin-dUTP nick end-labeling (TUNEL) assay, according to the manufacturer's instructions (EMD Biosciences). Following various treatments, neurons were washed with cold PBS, fixed with 4% paraformaldehyde, and then placed in equilibrating buffer and incubated in a reaction buffer containing TdT and dUTP for 60 min at 37°C. After rinsing, the cells were incubated with terminal deoxynucleotidyl transferase (TdT) to catalyze incorporation of fluorescein-dUTP at the free 3'-hydroxyl ends of the fragmented DNA. The percentage of TUNEL-positive cells (bright fluorescent green) were assessed by analysis of digitized images from 5 or more microscopic fields of TUNEL-stained cells from TIFF files (Adobe Photoshop version 7.0).

Protein determination

Protein concentrations were determined by the Bradford protein assay (Bradford et al., 1976) using bovine serum albumin to prepare standard curves.

Statistical analyses

Saturation curves and competition curves were analyzed using Prism (GraphPad Software). Other statistical analyses was performed by Student's *t*-test and analysis of variance (ANOVA) using Statistical Package for the Social Sciences (SPSS, Chicago, IL).

Results

NF- κ B regulates basal level of A₁AR expression

The absence of p50 protein in the p50^{-/-} mice was confirmed by Western blotting, performed on the cytosolic fraction of the spleen in the F2 and p50^{-/-} mice (Fig. 1, n=3 for each strain). A band equivalent to the p50 subunit protein was not detected in the p50^{-/-} mice but evident in the F2 mice. p65 subunit protein analyses revealed no change between the strains (data not shown).

To evaluate the role of NF- κ B in A₁AR regulation under normal conditions, brain regions from both strains of mice were analyzed for A₁AR binding. Quantitation of the A₁AR by single point binding assays (using 1 nM [³H]-DPCPX) indicate lower A₁AR levels in the cortex, hippocampus, brain stem, and hypothalamus in the p50^{-/-} mice than in the F2 mice. The levels of [³H]-DPCPX binding were 126 ± 9 and 83 ± 5 fmol/mg protein in the cortex obtained from the F2 and p50^{-/-} mice, respectively. The respective changes in F2 and p50^{-/-} mice were 93 ± 1 and 66 ± 6 fmol/mg protein in the hippocampus, 69 ± 3 and 48 ± 1 fmol/mg protein in the brain stem and 33 ± 2 and 22 ± 5 fmol/mg protein in the hypothalamus (Fig. 2A) (n = 4 per strain for each brain region, p<0.05). The difference in radioligand binding was also evident when full saturation curves were performed (Fig. 2B). Maximal binding capacity (B_{max}) was significantly lower in cortex from p50^{-/-} mice as compared to F2 mice (151 ± 62 and 479 ± 181 fmol/mg protein, respectively) (Fig.2B; n=5; p < 0.05). The equilibrium dissociation constants (K_d) did not differ between the two strains (Table 1.) (1.2 ± 0.4 and 1.1 ± 0.5 nM for F2 and p50^{-/-} mice, respectively).

To determine whether agonists interact similarly with the A₁AR in F2 and p50^{-/-} mouse, we performed competition curves using the agonist *R*-PIA competing for [³H]-DPCPX binding sites (Fig. 2C). Analyses of competition binding data using Graph Pad Prism software indicate preference of a two-state fit versus a one-state fit. The high affinity (K_H) values and the percentage of receptors in the high-affinity state did not differ between the two strains (Table 1). However, the low-affinity constant (K_L) of the receptors were statistically different in F2 and p50^{-/-} mice (Table 1) (n = 4 per strain, p < 0.05).

Affinity purification of the A₁AR from cortical membranes, followed by radio-iodination and visualization of the purified receptor (~36 kDa protein) on SDS-PAGE, revealed significantly lower labeling in the cortices obtained from p50^{-/-} versus F2 mice (Fig. 3A) (n=4 in each for each strain). The receptor was visualized as a 36-kDa protein band. In addition, single point radioligand binding assays performed on the affinity-purified receptor fractions from F2 and p50^{-/-} mice revealed ~30% less binding of the radioligand in the p50^{-/-} mouse (Fig. 3B). To determine whether the decrease in radioligand binding and A₁AR protein levels in the p50^{-/-} mice is associated with a decrease in the steady state levels of A₁AR mRNA, we performed real time PCR studies on cortical samples. This analysis revealed an ~35% reduction in A₁AR mRNA in p50^{-/-} mice, compared to F2 mice (Fig. 3 C,D) (n=6 per strain; p<0.005, Student's *t* test).

The lower A₁AR level in the p50^{-/-} mice was further confirmed by immunocytochemistry using A₁AR monoclonal antibody. This antibody revealed specific labeling in cortical layer 2 in the frontal cortex. Sporadic staining was also observed in the layer 3 and 4 of the cortex in both strains of mice. Labeling was not detected in the absence of primary antibody (data not shown). Comparison of similar cortical sections from F2 and p50^{-/-} mice revealed lower staining intensity in all of the cortical layers of the p50^{-/-} mice (Fig. 4B,C) (n=3 per strain). A cresyl violet-stained cortical section from the F2 animal, taken at the level where immunostained sections were obtained, is depicted in Fig. 4A.

To further extend our analyses, A₁AR binding was evaluated in peripheral tissues and was found to be lower in most of the tissues in the p50^{-/-} vs. F2 mice [(adrenal glands: F2, 8.7 ± 0.8; p50^{-/-}, 4.9 ± 0.4 fmol/mg protein; kidneys: F2, 5.7 ± 0.7; p50^{-/-}, 3.6 ± 0.2 fmol/mg protein; spleen: F2, 5.9 ± 1.5; p50^{-/-}, 4.7 ± 0.5 fmol/mg protein) (n = 4 per strain per region; p,0.05)]. In contrast, binding was slightly greater in the heart of p50^{-/-} mice (F2, 4.3 ± 0.02; p50^{-/-}, 5.8 ± 0. fmol/mg protein) (p<0.05, n=4 per strain).

Clonal cell lines are an ideal model to study changes in AR expression following different *in vivo* manipulations. To provide additional evidence for a role of NF-κB in the regulation of basal A₁AR expression, we compared A₁AR binding in normal rat pheochromocytoma (PC12) cells and in cells expressing the mutant form of IκB-α. Previous studies from our laboratory have characterized the A₁AR expression in PC12 cells (Jhaveri et al., 2006). Single point binding analysis revealed that binding in normal and mutant PC12 cells was 17.5 ± 2.4 fmol/mg protein and 11.8 ± 1.2 fmol/mg protein, respectively (n=6 per group; p<0.05 by Student's *t* test).

Cortical G-protein expression is altered in the p50^{-/-} mice

Cortical G-protein expression was evaluated to assess functional aspects of A₁AR signaling in the F2 and p50^{-/-} mice. Cortical G_{αi1} protein expression was not different between the two strains (F2, 0.8±0.4; p50^{-/-}, 0.9±0.4; n = 6 per strain) (Fig. 5 A,C). Cortical G_{αi3} protein was lower in the p50^{-/-} mice (1.7 ± 0.4 normalized units) as compared to 0.9 ± 0.2 normalized units in the F2 mice (Fig. 5 A,C) (p<0.05; n=5 for each strain). On the other hand, the protein expression of both G_{αo} and G_β were higher in the p50^{-/-} mice (Fig. 5 B,C) (F2, n = 3; p50^{-/-} = 4), as compared to the F2 mice. The values for cortical G_{αo} were 0.3 ± 0.1 and 0.7 ± 0.2 (p<0.05) and for G_β were 0.8 ± 0.4 and 2.4 ± 0.2 normalized units (p<0.05), in the F2 and p50^{-/-} mice, respectively.

Abrogation of LPS-mediated induction in A₁AR in p50^{-/-} mouse

Since LPS is a potent activator of NF-κB *in vivo* (Glezer et al., 2003), we next determined its impact on A₁AR protein and mRNA in cortices of F2 and p50^{-/-} mice. Radioligand binding studies to quantify cortical A₁AR 4 h after intraperitoneal administration of LPS (10μg), a time point associated with induction of A₁AR in a previous study (Jhaveri et al., 2006). In F2 mice, administration of LPS increased cortical A₁AR binding from 100 ± 10 fmol/mg protein (saline controls) to 163 ± 22 fmol/mg protein in the LPS-treated mice (n = 4 per group; p<0.05 by Student's *t* test). LPS also increased A₁AR mRNA expression by 78% ± 2.3 in the LPS treated F2 mice as compared to saline treated mice (Fig. 6A,B) (p<0.05; n=4 per group). In contrast, [³H]-DPCPX binding and mRNA expression were not altered by LPS in cortices obtained from p50^{-/-} mice (Fig. 6A,B) (n=4 per group). Similarly, LPS induced A₁AR binding in the brain stem of F2 mice (saline treated, 77.8 ± 1.6 fmol/mg protein; LPS treated, 105.7 ± 4.9 fmol/mg protein) (Fig. 6C; n=4 per group; p<0.05). However, A₁AR binding was lower in the brain stem of LPS treated p50^{-/-} mice (30.8 ± 3.1 fmol/mg protein) as compared to saline treated p50^{-/-} mice (54.4 ± 5.9 fmol/mg protein) (Fig. 6C; n=4; p<0.05).

Greater anti-apoptotic efficacy of A₁AR agonist in primary cortical neuron cultures from F2 versus p50^{-/-} mice

To determine a potential functional significance of the lower expression of cortical A₁AR in p50^{-/-} mice, cortical neurons were prepared from F2 and p50^{-/-} mice and cultured for 6 days. A percentage of the cultured cells demonstrated apoptosis, as evidenced by TUNEL staining (Fig. 7). However, the percentage of TUNEL positive cells was greater in the neurons cultured from p50^{-/-} mice (42±6%) versus F2 mice (11±1%). Incubation of cultures with R-PIA (1 μM) reduced the the percentage of apoptotic cells to 4±1% in F2 mice and to 25±3% in p50^{-/-} mice. This protective action appeared to be mediated via the A₁AR since it was reversed by the selective A₁AR antagonist DPCPX (apoptotic cells were 11±1% and 32±5%, for F2 and p50^{-/-} mice, respectively) (Fig. 7). As evidenced from these data, A₁AR activation conferred a greater degree of protection to cortical neurons obtained from F2 versus p50^{-/-} mice (64±9% inhibition in F2 versus 40±7% inhibition in p50^{-/-} mice). DPCPX added alone enhanced cell killing to 26±4% and 89±9%, for F2 and p50^{-/-} cortical neurons, respectively.

Discussion

The major finding of this study is that mice which lack the p50 subunit of NF-κB show reduced A₁AR expression in various brain regions and organs, as compared to genetically intact F2 mice. This finding indirectly suggests constitutive basal NF-κB activity influences A₁AR expression in both central nervous system (CNS) and peripheral tissues. Thus, A₁AR expression could be regulated by NF-κB not only under conditions of oxidative stress and infectious challenge (Nie et al., 1998; Jajoo et al., 2006), which lead to increased NF-κB activity, but also under normal physiological conditions.

Previous studies suggest that oxidative stress induced by chemotherapeutic agents, including cisplatin and anthracyclines, increases A₁AR expression and promoter activity via NF-κB activation (Nie et al., 1998). A consensus sequence for NF-κB was detected 623 bases upstream of promoter A transcription start site in plasmid construct pBLPnif/PmtA (Ren and Stiles, 1995) which regulates transcription in response to reactive oxygen species production. A second NF-κB consensus sequence located 306 bases upstream of the second start site of the human A₁AR gene did not confer significant NF-κB activity (Nie et al., 1998). NF-κB activation and subsequent induction of A₁AR in the cochlea is also observed in response to noise exposure (Ramkumar et al., 2004) and in rat kidney by cisplatin (Bhat et al., 2002). NF-κB has also been implicated in mediating sleep rebound after sleep deprivation (Basheer et al., 2001). AP-1 transcription sites have also been detected in the A₁AR promoter region (Ren and Stiles, 1995). However, inhibition of the MAP kinase pathway, an upstream activator of AP-1 transcription factors, did not inhibit A₁AR expression (Ramkumar et al., unpublished data), strongly indicative of a crucial role of NF-κB in the regulation of A₁AR expression. Our data show that A₁AR levels in several brain regions and organs are lower in the p50^{-/-} mice, as compared to F2 mice. The lower cortical protein expression is paralleled by a corresponding decrease in A₁AR mRNA, suggesting the possibility that transcription of the A₁AR gene is reduced in p50^{-/-} mice. However, an alternative possibility is that the reduced amount of A₁AR transcript could reflect decreased stability of this mRNA in the p50^{-/-} mice. Defective receptor transport, endosomal sorting, and insertion into the membrane could also contribute to reduced A₁AR binding in various regions.

The genetic absence of p50 appears to significantly affect kainate-induced κB DNA binding activity in the hippocampus (Yu et al., 1999) and possibly in other brain regions, suggesting functional deficit in NF-κB in the p50^{-/-} mice. NF-κB plays a central role in maintaining neuronal survival (Barger et al., 1995; Maggirwar et al., 1998). Hippocampal pyramidal neurons from p50^{-/-} mice demonstrate greater kainate excitotoxicity than do normal wild type mice (Yu et al., 1999). p50^{-/-} mice also exhibit increased auditory nerve degeneration and

sensitivity to noise-induced hearing loss (Lang et al., 2006). Furthermore, under normal physiological conditions, NF- κ B activity is constitutive in the brain and appears to be essential for neuronal survival during development and in the adult (Bhakar et al., 2002). However, the signals responsible for the maintenance of constitutive NF- κ B are not clearly defined. These signals could result from constitutive paracrine or autocrine activation loops (Bhakar et al., 2002). Constitutive activity could also derive from retrograde signaling after activation of NF- κ B at the nerve terminal by neurotransmitters. Such retrograde transport of NF- κ B has been demonstrated in neurons after stimulation with various agents (Wellman et al., 2001). The implication of these findings is that neuronal survival might be intricately linked to synaptic activity and NF- κ B activity.

Our data suggest that constitutive NF- κ B activity could be important, at least in part, in regulating the expression level of the A₁AR under normal physiological conditions. This was evident in a number of brain regions (cortex, hippocampus, brain stem and hypothalamus and in non-neuronal tissues such as the kidney, spleen, and adrenal gland. Some brain regions (e.g. cortex and hippocampus) have high constitutive NF- κ B activity, which could be related to the reduced A₁AR expression in these regions in the p50^{-/-} mice (Bakalkin et al., 1993). However, NF- κ B activity has not been determined systematically in other brain regions in a manner that would allow us to conclude that the regions showing reduced A₁AR expression in the p50^{-/-} mice were also those with high constitutive activity in the F2 mice. It is also not clear whether the different tissue levels of A₁AR expression grossly defined by single concentration radioligand binding studies reflect differences in the activity of NF- κ B intrinsic to these tissues. Certainly, other factors, such as subunit composition of the NF- κ B homodimers could be important determinants of transcriptional efficacy. Different brain regions might contain NF- κ B of different subunit composition, which could in turn mediate different specific functions. As in other cell types, p50/p65 is the most commonly occurring heterodimer combination in the CNS (Bakalkin et al., 1993; Meffert and Baltimore, 2005) although other subunit compositions (e.g. p50 homodimers, p50/c-Rel, and p65/c-Rel) have also been detected (Bakalkin et al., 1993). Nonetheless, the relative preponderance of p50/p65 heterodimers in the adult brain may account for the generalized reduction in A₁AR that we measured in different brain regions of p50^{-/-} mice, as well as the higher number of these receptors in the various brain regions compared to other tissues assessed in the present study.

In addition to NF- κ B, another factor which determines the levels of A₁AR produced by a cell is posttranslational mRNA processing. Tissues which express low levels of the A₁AR express transcripts containing exons 4, 5 and 6, while those which express high levels of A₁AR (such as brain, kidney, testis) express transcripts containing exons 3, 5 and 6 and exon 4, 5 and 6 (Ren and Stiles, 1994). The inhibitory role of exon 4 is determined by the presence of two upstream ATG start codons (Ren and Stiles, 1994).

Our data also reveal that levels of G protein α and β subunits are also altered in the cortex of the p50^{-/-} mice as compared to the wild type mice. More specifically, levels of the G_{ai3} proteins were significantly lower in the cortices of p50^{-/-} mice, while both cortical G_{ao} and G β were higher in these mice. Moreover, levels of another prominent isoform G_{ai1} was similar between the two strains of mice. Whether the expression of these G protein subunits are regulated by NF- κ B or by other factors is not clear. Based on our data, the decrease in G_{ai3} could reflect a positive regulation of this G protein subunit via a p50 containing NF- κ B complex. In contrast, the levels of G_{ao} and G β could be negatively regulated by this complex. NF- κ B. Based on our data, if these subunits are regulated by NF- κ B, then they are regulated differentially. Regulation of two heterotrimeric G protein subunits by NF- κ B has recently been described. These reports show induction of G_{ai2} in K562 cells (Arinze and Kawai, 2005) and repression of G_{as} proteins in human myometrium (Chapman et al., 2005) and raise the possibility that other G protein subunits are similarly regulated by NF- κ B. An alternative hypothesis is that the changes in G

protein subunits could reflect changes in G protein coupled receptor expression and regulation of downstream signaling. For example, previous studies have shown coordinate changes in receptor and G protein expression after receptor desensitization and sensitization, suggesting that the levels of the G proteins are directly influenced by receptor function (for review see Stiles, 1992). However, the divergent regulation of the different $G_{\alpha i}$ and β subunits would discount such a possibility.

Despite changes in G_{α} subunits, we observed no change in agonist high affinity (G protein-coupled) state of the A_1AR . This could suggest that the increases in $G_{\alpha i1}$ and $G_{\alpha o}$ subunits could cancel out any functional deficits in $G_{\alpha i3}$. However, this explanation is purely speculative since Freissmuth et al. (1992) showed, at least for the recombinant $G_{\alpha i}$ and $G_{\alpha o}$ subunits, a 10-fold higher affinity of the A_1AR for $G_{\alpha i3}$ than for the other $G_{\alpha i}$ or $G_{\alpha o}$ subunits. Coordinate regulation of G protein-coupled receptors and heterotrimeric G protein subunits by NF- κB appears to be an intriguing idea since it provides an additional level of control of receptor signaling. Coordinate regulation of the $AR_{2A}AR$ and $G_{\alpha s}$ and $G_{\alpha olf}$ proteins was similarly observed in striata of $p50^{-/-}$ mice and leads to increased activation of $A_{2A}AR$ signaling cascade (Xie et al., 2006). The reduced ability of R -PIA to decrease apoptosis in neuron cultures obtained from $p50^{-/-}$ versus F2 mice could reflect the lower levels of A_1AR expression, rather than their ability to couple with G proteins, since receptor-G protein coupling (as defined by agonist high affinity binding) was not altered. The enhancement in apoptosis induced by DPCPX would support a role of endogenously produced adenosine in mediating protection under normal culture conditions. Furthermore, the increased apoptosis could reflect a decreased ability of the $p50^{-/-}$ neurons to adapt to the stress of *in vitro* culturing, better than the F2 mice. In spite of the apparent difference in F2 and $p50^{-/-}$ response to R -PIA, our data highlights the importance of A_1AR activation in mediating cell viability under normal culture conditions, as evidenced by the finding that DPCPX significantly increased apoptosis in neuronal cultures obtained from both F2 and $p50^{-/-}$ mice.

Our data do not rule out the possibility of compensation by other members of the κB family in response to deletion of the p50 subunit. $p50^{-/-}$ mice can form alternative p52:p65 dimers, but this dimer does not compensate functionally for p50 (Kunsch et al., 1992; Franzoso et al., 1998; Hoffmann et al., 2003). The interaction of both p50 and p65 components is required for normal NF- κB binding and transcriptional activation of specific genes, and the lone availability of either of these subunits may be insufficient for binding of or transcriptional activation by NF- κB (Kunsch et al., 1992). Finally, not only does the transcription of individual genes require a specific NF- κB dimer combination (Pizzi et al., 2002; Hoffmann et al., 2003), but even single nucleotide differences in the κB sites of the gene can significantly alter specific NF- κB dimer requirements (Leung et al., 2004). Thus, each transcriptional event requires recruitment of different dimer combinations. Moreover, our study highlights the fact that even members of the κB family that lack transactivation domains (such as p50) can be highly relevant in transcriptional regulation of a gene as prominent as A_1AR .

In conclusion, A_1AR expression and binding are modulated by NF- κB in various brain regions and peripheral tissues. Although this study focused on the impact of the p50 subunit of NF- κB , a future challenge is to delineate the involvement of other members of the κB family and associated co-activator proteins that underlie receptor regulation by pathologic and non-pathologic stimuli. A genetic approach using such knockout mice models provides a powerful tool to characterize the regulation of A_1AR in the brain.

Acknowledgement

This work was supported by NIH grant # R01-7543 and by the Excellence in Academic Medicine program of the SIU School of Medicine.

Abbreviations

A₁AR, Adenosine A₁ receptor; ADA, Adenosine deaminase; AR, Adenosine receptor; B_{max}, Maximal binding capacity; CHAPS, Polyethylneimine and 3-[(3-cholamidopropyl) dimethylammonio]-1 propanesulphonate; CNS, Central nervous system; GAPDH, Glyceraldehyde phosphate 3-dehydrogenase; GPCR, G-protein coupled receptor; [³H]-DPCPX, ([³H]8-cyclopentyl-1,3-di[2',3'-³H] propylxanthine; K_d, Equilibrium dissociation constant; LPS, Lipopolysaccharide; mI κB-α, Mutant I κB-α; NF-κB, Nuclear factor – kappa B; PBS, Phosphate buffered saline; PC12 cells, Rat pheochromocytoma cells.

References

- Arinze II, Kawai Y. Transcriptional activation of the human G_{αi2} gene promoter through nuclear factor-κB and antioxidant response elements. *J Biol Chem* 2005;280:9786–9795. [PubMed: 15640523]
- Bakalkin G, Ya, Yakovleva T, Terenius L. NF-κB-like factors in the murine brain. Developmentally-regulated and tissue-specific expression. *Brain Res Mol Brain Res* 1993;20:137–146. [PubMed: 8255175]
- Barger SW, Horster D, Furukawa K, Goodman Y, Kriegstein J, Mattson MP. Tumor necrosis factors alpha and beta protect neurons against amyloid beta- peptide toxicity: evidence for involvement of a κB-binding factor and attenuation of peroxide and Ca²⁺ accumulation. *Proc Natl Acad Sci U SA* 1995;92:9328–9332.
- Basheer R, Rainnie DG, Porkka-Heiskanen T, Ramesh V, McCarley RW. Adenosine, prolonged wakefulness, and A₁-activated NF-κB DNA binding in the basal forebrain of the rat. *Neuroscience* 2001;104:731–739. [PubMed: 11440805]
- Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. *Nature* 1995;376:167–170. [PubMed: 7603567]
- Bhakar AL, Tannis LL, Zeindler C, Russo MP, Jobin C, Park DS, MacPherson S, Barker PA. Constitutive nuclear factor-κB activity is required for central neuron survival. *J Neurosci* 2002;22:8466–8475. [PubMed: 12351721]
- Bhat SG, Mishra S, Mei Y, Nie Z, Whitworth CA, Rybak LP, Ramkumar V. Cisplatin up-regulates the adenosine A₁ receptor in the rat kidney. *Eur J Pharmacol* 2002;442:251–264. [PubMed: 12065079]
- Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;72:248–254. [PubMed: 942051]
- Brewer G, Torricelli J, Evege E, Price P. Optimized survival of hippocampal neurons in B27 supplemented Neurobasal, a new serum-free medium combination. *J Neurosci Res* 1993;32:567–576. [PubMed: 8377226]
- Brewer G. Isolation and culture of adult rat hippocampal neurons. *J Neurosci Methods* 1997;71:143–155. [PubMed: 9128149]
- Chapman NR, Smyrniak I, Anumba DOC, Europe-Finner GN, Robson SC. Expression of the GTP-binding protein (G_{αs}) is repressed by nuclear factor κB RelA subunit in human myometrium. *Endocrinology* 2005;146:4994–5002. [PubMed: 16081638]
- Dolphin AC, Archer ER. An adenosine agonist inhibits and a cyclic AMP analogue enhances the release of glutamate but not GABA from slices of rat dentate gyrus. *Neurosci Lett* 1983;43:49–54. [PubMed: 6142434]
- Evans MC, Swan JH, Meldrum BS. An adenosine analogue, 2-chloroadenosine, protects against long term development of ischaemic cell loss in the rat hippocampus. *Neurosci Lett* 1987;83:287–292. [PubMed: 3441311]
- Ford MS, Nie Z, Whitworth C, Rybak LP, Ramkumar V. Up-regulation of adenosine receptors in the cochlea by cisplatin. *Hear Res* 1997;111:143–152. [PubMed: 9307320]
- Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A, Grinbery A, Tran T, Schariton-Kersten T, Anver M, Love P, Brown K, Siebenlist U. Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal centre reactions, and splenic microarchitecture. *J Exp Med* 1998;187:147–159. [PubMed: 9432973]

- Fredholm BB, Dunwiddie TV. How does adenosine inhibit transmitter release? *Trends Pharmacol Sci* 1988;9:130–134. [PubMed: 2907698]
- Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev* 2001;53:527–552. [PubMed: 11734617]
- Freissmuth M, Schutz W, Linder ME. Interactions of the bovine brain A₁-adenosine receptor with recombinant G protein α -subunits. *J Biol Chem* 1991;266:17778–17783. [PubMed: 1917922]
- Glezer I, Munhoz CD, Kawamoto EM, Marcourakis T, Avellar MC, Scavone C. MK-801 and 7-Ni attenuate the activation of brain NF- κ B induced by LPS. *Neuropharmacology* 2003;45:1120–1129. [PubMed: 14614955]
- Hoffmann A, Leung TH, Baltimore D. Genetic analysis of NF- κ B/Rel transcription factors defines functional specificities. *EMBO* 2003;22:5530–5539.
- Jajoo S, Mukherjea D, Pingle SC, Sekino Y, Ramkumar V. Induction of adenosine A₁ receptor expression by pertussis toxin via an ADP ribosylation independent pathway. *J Pharmacol Exp Ther* 2006;317:1–10. [PubMed: 16322354]
- Jhaveri KA, Toth LA, Sekino Y, Ramkumar V. Nitric oxide serves as an endogenous regulator of brain A₁ adenosine receptor. *J Neurochem* 2006;99:42–53. [PubMed: 16987234]
- Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA. Constitutive NF- κ B activity in neurons. *Mol Cell Biol* 1994;14:3981–3992. [PubMed: 8196637]
- Kostopoulos GK, Phillis JW. Purinergic depression of neurons in different areas of the rat brain. *Exp Neurol* 1977;55:719–724. [PubMed: 858344]
- Kunsch C, Ruben SM, Rosen CA. Selection of optimal κ B/Rel DNA-binding motifs: interaction of both subunits of NF- κ B with DNA is required for transcriptional activation. *Mol Cell Biol* 1992;12:4412–4421. [PubMed: 1406630]
- Lang H, Schulte BA, Zhou D, Smythe N, Spicer SS, Schmiedt RA. Nuclear factor- κ B deficiency is associated with auditory nerve degeneration and increased noise-induced hearing loss. *J Neurosci* 2006;26:3541–3550. [PubMed: 16571762]
- Leung TH, Hoffmann A, Baltimore D. One nucleotide in a κ B site can determine cofactor specificity for NF- κ B dimers. *Cell* 2004;118:453–464. [PubMed: 15315758]
- Maggirwar SB, Sarmiere PD, Dewhurst S, Freeman RS. Nerve growth factor-dependent activation of NF- κ B contributes to survival of sympathetic neurons. *J Neurosci* 1998;18:10356–10365. [PubMed: 9852573]
- Meffert MK, Baltimore D. Physiological functions for brain NF- κ B. *Trends Neurosci* 2005;28:37–43. [PubMed: 15626495]
- Nie Z, Mei Y, Ford M, Rybak L, Marcuzzi A, Ren H, Stiles GL, Ramkumar V. Oxidative stress increases A₁ adenosine receptor expression by activating nuclear factor- κ B. *Mol Pharmacol* 1998;53:663–669. [PubMed: 9547356]
- Nie Z, Mei Y, Malek RL, Marcuzzi A, Lee NH, Ramkumar V. A role of p75 in NGF-mediated down-regulation of the A_{2A} adenosine receptors in PC12 cells. *Mol Pharmacol* 1999;56:947–954. [PubMed: 10531399]
- Ochiishi T, Chen L, Yukawa A, Saitoh Y, Sekino Y, Arai T, Nakata H, Miyamoto H. Cellular localization of adenosine A₁ receptors in rat forebrain: immunohistochemical analysis using adenosine A₁ receptor-specific monoclonal antibody. *J Comp Neurol* 1999;411:301–316. [PubMed: 10404255]
- Olah ME, Stiles GL. Adenosine receptors. *Annu Rev Physiol* 1992;54:211–225. [PubMed: 1373278]
- Pingle S, Mishra S, Marcuzzi A, Bhat S, Sekino Y, Rybak L, Ramkumar V. Osmotic diuretics induce adenosine A₁ receptor expression and protect renal proximal tubular epithelial cells against cisplatin-mediated apoptosis. *J Biol Chem* 2004;279:43157–43167. [PubMed: 15272017]
- Pizzi M, Goffi F, Boroni F, Benarese M, Perkins SE, Liou HC, Spano P. Opposing roles for NF- κ B/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin-1 β . *J Biol Chem* 2002;277:20717–20723. [PubMed: 11912207]
- Ralevic V, Burnstock G. Receptors for purines and pyrimidines. *Pharmacol Rev* 1998;50:413–492. [PubMed: 9755289]
- Ramkumar V, Whitworth CA, Pingle SC, Hughes LF, Rybak LP. Noise induces A₁ adenosine receptor expression in the chinchilla cochlea. *Hear Res* 2004;88:47–56. [PubMed: 14759570]

- Ren H, Stiles GL. Posttranslational mRNA processing as a mechanism for regulation of human A₁ adenosine receptor expression. *Proc Natl Acad Sci USA* 1994;91:4864–4866. [PubMed: 8197148]
- Ren H, Stiles GL. Separate promoters in the human A₁ adenosine receptor gene direct the synthesis of distinct messenger RNAs that regulate receptor abundance. *Mol Pharmacol* 1995;48:975–980. [PubMed: 8848013]
- Rivkees SA, Price SL, Zhou FC. Immunohistochemical detection of A₁ adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia. *Brain Res* 1995;677:193–203. [PubMed: 7552243]
- Rubio R, Berne RM, Bockman EL, Curnish RR. Relationship between adenosine concentration and oxygen supply in rat brain. *Am J Physiol* 1975;228:1896–1902. [PubMed: 168787]
- Rudolph KA, Schubert P, Parkinson FE, Fredholm BB. Neuroprotective role of adenosine in cerebral ischemia. *Trends Pharmacol Sci* 1992;13:439–445. [PubMed: 1293870]
- Schwarz EM, Badorff C, Hiura TS, Wessely R, Badorff A, Verma IM, Knowlton KU. NF- κ B-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice. *J Virol* 1998;72:5654–5660. [PubMed: 9621024]
- Sha WC, Liou HC, Tuomanen EI, Baltimore D. Target disruption of the p50 subunit of NF- κ B leads to multifocal defects in immune responses. *Cell* 1995;80:321–330. [PubMed: 7834752]
- Soong R, Beyser K, Basten O, Kalbe A, Rueschoff J, Tabiti K. Quantitative reverse transcription – polymerase chain reaction detection of cytokeratin 20 in noncolorectal lymph nodes. *Clin Cancer Res* 2001;7:3423–3429. [PubMed: 11705858]
- Stiles GL. Adenosine receptors. *J Biol Chem* 1992;267:6451–6454. [PubMed: 1551861]
- Tucker AL, Linden J. Cloned receptors and cardiovascular responses to adenosine. *Cardiovasc Res* 1993;27:62–67. [PubMed: 8458033]
- Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF- α induced apoptosis by NF- κ B. *Science* 1996;274:787–789. [PubMed: 8864120]
- Van Wylen DG, Park TS, Rubio R, Berne RM. Increases in cerebral interstitial fluid adenosine concentration during hypoxia, local potassium infusion, and ischemia. *J Cereb Blood Flow Metab* 1986;6:522–528. [PubMed: 3760038]
- Wellmann H, Kaltschmidt B, Kaltschmidt C. Retrograde transport of transcription factor NF- κ B in living neurons. *J Biol Chem* 2001;276:11821–11829. [PubMed: 11096106]
- Xie X, Toth LA, Ramkumar V. Adenosine A_{2A} receptor downstream signaling molecules are increased in striata of mice lacking nuclear factor (NF)- κ B p50 subunit. *Society for Neuroscience*. 2006Abstract 721.2.
- Yu Z, Zhou D, Bruce-Keller AJ, Kindy MS, Mattson MP. Lack of the p50 subunit of nuclear factor- κ B increases the vulnerability of hippocampal neurons to excitotoxic injury. *J Neurosci* 1999;19:8856–8865. [PubMed: 10516305]




Figure 1. p50 protein is absent in the p50^{-/-} mice
SDS-PAGE analysis and Western blotting of cytosolic fraction of spleen from F2 and p50^{-/-} mice confirmed the absence of the p50 protein in the p50^{-/-} mice. Proteins were normalized to internal control β -actin (n = 3 per strain).




Figure 2. Reduction in $A_1\text{AR}$ in $p50^{-/-}$ mouse brain

A, $A_1\text{AR}$ binding in F2 and $p50^{-/-}$ mice ($n=4$ per strain) was quantified in membrane fractions (50 μg) of cortex, hippocampus, brain stem, and hypothalamus using the specific $A_1\text{AR}$ antagonist $[^3\text{H}]\text{-DPCPX}$ (1 nM). Values are expressed as fmol/ mg protein and represent mean \pm SEM for three independent experiments with samples assayed in triplicate (*, $p < 0.05$, Student's t -test). **B**, Saturation binding analysis of cortical membrane for $A_1\text{AR}$ with $[^3\text{H}]\text{-DPCPX}$ in the absence (total binding) or presence (nonspecific binding) of 0.5 mM theophylline revealed lower maximal binding in the $p50^{-/-}$ mice with no change in affinity. A representative curve representing specific binding is shown for F2 and $p50^{-/-}$ mice. Curves were fitted to a one-site model using GraphPad Prism ($n = 5$ for F2; $n = 4$ for $p50^{-/-}$). **C**, Competition analyses of cortical $A_1\text{AR}$ in F2 and $p50^{-/-}$ mice revealed similar affinity in F2 and $p50^{-/-}$ mice. Cortical membranes were incubated with 1nM $[^3\text{H}]\text{-DPCPX}$ and increasing concentrations of AR agonist $R\text{-PIA}$. Data represent percentage of specific binding ($n = 4$ per strain) and show the mean \pm SEM of four independent experiments, with samples assayed in duplicate. The curves were generated using a curve fitting program in GraphPad Prism according to a two state model.




Figure 3. Purified cortical A₁AR and mRNA expression are lower in p50^{-/-} mice

A, Immunopurified A₁AR from cortical membrane fractions of F2 and p50^{-/-} mice (n = 4 per strain) were iodinated and analyzed by SDS-PAGE (12%). Equal numbers of counts were loaded onto gels and the A₁AR protein was identified as a 36 kDa protein. The level of this protein was lower in the p50^{-/-} mice compared to F2 mice. **B**, Single point binding assay of immunopurified cortical membrane using [³H]-DPCPX (1nM) revealed 30% less A₁AR in p50^{-/-} mice as compared to F2 mice. p50^{-/-} values were expressed as percentage of F2 values and represent the mean ± SEM of four similar experiments (n= 4 per strain; p<0.05). **C**, Comparative quantitative PCR analysis revealed approximately 35 ± 5.6 % less A₁AR mRNA expression in p50^{-/-} mice. Data was normalized to the internal control gene GAPDH and expressed as fold change of A₁AR with respect to F2 mice. Data represent mean ± SEM (n= 6 for each strain) (p < 0.01, Student's *t* test). Asterisk indicates significance of p < 0.05 or p < 0.01 by Student's *t*-test in the p50^{-/-} mice compared to the F2 mice. **D**, The threshold for detection of fluorescence occurs at a higher cycle number in p50^{-/-} mice as compared to the F2 mice.






Figure 4. A₁AR cortical immunohistochemistry in F2 and p50^{-/-} mice

A, Cresyl violet staining in F2 mice. The different layers in the figure are Layer I (molecular), Layer II-III (small pyramidal cells), Layer IV (granular layer), Layer V-VI (infragranular layers). WM represents the white matter. **B,** Paraformaldehyde stained sections were incubated with monoclonal antibody for the A₁AR and visualized using a TRITC labeled mouse secondary antibody. TRITC labeling detected as red fluorescence in layer 2 of the frontal cortex in the F2 and p50^{-/-} mice. **C,** Fluorescence intensity analysis (n=3 per strain). Asterisk indicates statistical significance between F2 and p50^{-/-} mice by Student's t test).




Figure 5. Cortical G-protein expression in F2 and p50^{-/-} mice
 SDS-PAGE analysis and Western blotting of the membrane fraction (40 μg) for different G-protein isoforms in F2 and p50^{-/-} mice revealed different expression between the two strains. Incubation of samples with rabbit polyclonal antibodies for G_{α1}, G_{α3}, G_{α0}, and G_β was carried out. **A**, G_{α1} and G_{α3} (n = 5 per strain). **B**, G_{α0} and G_β, and **C**, proteins were normalized to β-actin (F2, n = 3; p50^{-/-} = 4) Asterisk indicates statistical significance between the two strains.




Figure 6. Cortical A₁AR expression in saline and LPS treated F2 and p50^{-/-} mice

A, A₁AR binding in cortical membrane (50 μg) fractions was measured in mice treated with saline (0.2 ml) or LPS (10 μg/0.2 ml). F2 mice showed 63% ± 4.8 more A₁AR binding at 4 h after LPS administration, whereas p50^{-/-} mice did not show any change in binding (n = 6 per group). Values represent mean ± SEM of three independent experiments with samples assayed in triplicate. Asterisks represent significance in LPS treated F2 mice compared to saline treated mice (p < 0.05). **B,** Comparative quantitative PCR analysis revealed approximately 78% ± 2.3 increased A₁AR expression in LPS treated F2 mice as compared to saline treated F2 mice while the p50^{-/-} mice did not show any change in A₁AR expression between saline and LPS treated mice. Data was normalized to the internal control gene GAPDH and expressed as fold change of A₁AR with respect to saline treated mice. Data represent mean ± SEM (n= 4 for each strain) (Asterisk indicates statistical significance from F2 mice, p < 0.01, Student's *t* test). **C,D** A₁AR binding in brain stem and hypothalamic membrane (50 μg) fractions measured in mice treated with saline or LPS (n = 4 per group per strain). Values represent mean ± SEM of three independent experiments with samples assayed in triplicate. Asterisks represent significance in LPS treated mice compared to saline treated mice (p < 0.05 by Student's *t* test).




Figure 7. Activation of A₁AR reduced apoptosis in cortical neuron cultures obtained from F2 and p50^{-/-} mice

Cortical neurons were obtained from mice and cultured for 6 days. Apoptotic cells were visualized by TUNEL assay, according to the manufacturer's instructions (EMD Biosciences). The percentage of TUNEL-positive cells was assessed by analysis of digitized images from 5 or more microscopic fields of stained cells. The data are presented as the percent mean ± SEM of TUNEL positive cells in cultures treated with R-PIA (1 μM) and/or DPCPX (1 μM). Asterisks (*) indicates statistically significant difference from F2 control group, (#) indicates statistically significant difference from R-PIA treated group, and '@' indicates statistical difference in p50 KO control group from F2 control group (p<0.05), respectively.

Table 1

Saturation and Affinity analysis for A₁AR in control F2 and p50^{-/-} mice.

Strain	B _{max} fmol	K _d nM	K _H nM	K _L μM	R _H %
F2	478.8±181.0	1.18±0.44	1.30±0.03	3.00±0.10	0.72
p50 KO	151.3±61.8 *	1.08±0.45	1.80±0.03	7.20±0.10 *	0.73

B_{max} and K_d are the maximal binding capacity and the affinity of the receptor for the ligand respectively. K_H and K_L are the high affinity and low affinity dissociation constants, respectively, calculated assuming a two-state model. R_H is the percentage of total receptors in the high affinity state. Values are mean ± SEM. Asterisk represents significant difference between the two strains and indicates p < 0.05 (Student's *t* test).